Premium
Risankizumab for the treatment of plaque psoriasis in adults
Author(s) -
Chaplin Steve
Publication year - 2019
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1812
Subject(s) - medicine , plaque psoriasis , psoriasis , dermatology
Risankizumab (Skyrizi) is an anti‐IL‐23 monoclonal antibody therapy for the treatment of plaque psoriasis in adults. This article discusses its clinical trial efficacy, adverse effects and place in therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom